MXCT
MaxCyte IncKey Statistics
About MaxCyte Inc
MaxCyte Inc. (MXCT) is a leading innovator in cell-engineering solutions, renowned for its proprietary Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins across diverse cell types. Catering to a broad spectrum of clients, including major biopharmaceutical companies and research institutions, MaxCyte plays a critical role in the rapidly evolving cell and gene therapy market. The company's advanced platforms are essential for the development of cutting-edge cell-based therapies and vaccines, positioning MaxCyte to capitalize on significant growth opportunities in the healthcare sector. With a steadfast dedication to advancing transformative treatment options, MaxCyte is well-equipped to address the escalating global demand for innovative therapeutic modalities.
Fundamentals
| Revenue (TTM) | $33.03M |
| Gross Profit (TTM) | $26.80M |
| EBITDA | $-40.22M |
| Operating Margin | -94.80% |
| Return on Equity | -23.60% |
| Return on Assets | -12.60% |
| Revenue/Share (TTM) | $0.31 |
| Book Value | $1.61 |
| Price-to-Book | 0.47 |
| Price-to-Sales (TTM) | 2.44 |
| EV/Revenue | 0.0162 |
| EV/EBITDA | -11.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -16.00% |
| Shares Outstanding | $106.86M |
| Float | $105.73M |
| % Insiders | 1.40% |
| % Institutions | 73.51% |
Historical Volatility
Volatility is currently expanding